论文部分内容阅读
Objective Immune thrombocytopaenia (ITP) is characterized by platelet destruction and megakaryocyte dysfunction resulting from autoantibodies induced by the polarization of Th1 and deficient regulatory T cells.Mesenchymal stem cells (MSCs) display not only stem cell multipotency but also robust immunosuppressive properties.However, MSCs from ITP patients do not exhibit conventional proliferative abilities and thus exhibit defects in immunoregulation, while the transplantation of health MSCs could improve platelet production and attenuate megakaryocytedysfunction by reversing the shift in the Th1/Th2 cytokine balance, suggesting that MSC impairment might be a mechanism involved in ITP.In addition, reversal of the defects in MSCs may represent a potential therapeutic alternative.Platelet-derived growth factor (PDGF) improves growth and survival in various cell types.Moreover, PDGF promotes MSCs proliferation.